RANCHO SANTA MARGARITA, Calif., Jan. 23, 2003 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) announced today that it is considering several proposals for funding of its research and operations and anticipates that its funding requirements will be met in the near term. The company is very pleased with the considerable interest in its activities and with the expanding recognition of the potential of its patented technology. Updates will be provided as progression occurs.
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. Detailed information about BioCurex may be obtained from their Website at http://www.biocurex.com.
Note:
Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.